Zentalis Pharmaceuticals (ZNTL) Projected to Release Quarterly Earnings on Tuesday

Key Points

• Zentalis Pharmaceuticals is expected to report Q3 2026 results on November 10, with analysts forecasting a loss of $0.58 per share. Its earnings call is scheduled for November 13 at 4:00 p.m. ET.
• The company reported a larger-than-expected loss of $0.59 per share in the prior quarter, missing consensus estimates by $0.10. Analysts project full-year and next-year losses of $2.11 and $2.21 per share, respectively.
• ZNTL shares recently traded near $1.88, well below their 52-week high of $6.95, while analyst sentiment remains a “Moderate Buy” with an average price target of $7.50. Major shareholder Group Walters also increased its stake by purchasing 4.335 million shares.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) is anticipated to release its Q3 2026 resultson Tuesday, November 10th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, analysts expect Zentalis Pharmaceuticals to post ($2.11) EPS for the current fiscal year and ($2.21) EPS for the next fiscal year.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL traded up $0.03 on Tuesday, reaching $1.88. 365,621 shares of the company's stock were exchanged, compared to its average volume of 1,530,732. The firm has a market cap of $134.38 million, a price-to-earnings ratio of -0.96 and a beta of 1.93. The stock has a fifty day simple moving average of $2.91 and a 200-day simple moving average of $3.44. Zentalis Pharmaceuticals has a 52 week low of $1.21 and a 52 week high of $6.95.

Insider Buying and Selling

In other news, major shareholder Group Walters purchased 4,335,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, August 14th. The stock was purchased at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the transaction, the insider directly owned 17,844,973 shares of the company's stock, valued at approximately $62,457,405.50. This trade represents a 32.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on ZNTL. Jefferies Financial Group upgraded shares of Zentalis Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 14th. Rodman & Renshaw began coverage on shares of Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a "buy" rating and a $11.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, October 19th. Wells Fargo & Company started coverage on Zentalis Pharmaceuticals in a report on Wednesday, September 30th. They issued an "equal weight" rating and a $5.00 price target for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a research report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $7.50.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc NASDAQ: ZNTL is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company's research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments.

Zentalis' lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.